Trial Profile
A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab combination followed by bevacizumab alone in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Sanofi
- 02 Dec 2008 Checked against ClinicalTrials.gov record.
- 03 Oct 2007 Status change from recruiting to discontinued.
- 08 Oct 2006 New trial record.